Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
news out
looks like they got the other outlets to pick up their German and Spain solar news.
DEVENTER, THE NETHERLANDS, May 17, 2006 (MARKET WIRE via COMTEX) -- GiraSolar Inc. (GRSR) is pleased to announce its subsidiary DutchSolar BV has completed a 1MWp cells supply obligation to a major German solar industry partner. DutchSolar BV overachieved on its projected supply of 1MWp with 16% in surplus of its obligations. Supply had initially begun with delays in December 05 and was expected to take well into H2 of 2006. The revenue value now exceeds well over 3M$ and payments have been received in full. It is expected that DutchSolar will continue the supply of cells to German counterparts and further cooperation will be sought.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=grsr&sid=0&o_symb=grsr&f...
GRSR - solar power play (1.20 x 1.30)
With the sector price to sales ratio average around 20, GiraSolar (GRSR) should be trading at $5.86 a share on a p/s ratio of just 8....READ THIS REPORT!
http://www.ludlowcapital.com/reports/grsr.htm
H5N1 cluster in Indonesia (very serious)
A cluster of H5N1 cases found in Indonesia which WHO says is very concerning and may signal the virus may actually be jumping from human to human.
http://www.bloomberg.com/apps/news?pid=10000080&sid=aCotPF_j.uIc
keep an eye on STTK, GNBT, TEDG, NVAX, SVA, and HEB
TEDG - China's largest vaccine producer...
TEDG - .45 x .48
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
OT: TEDG - China's largest vaccine producer
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
China BioPharma (TEDG) - bird flu vaccine
Im surprised TEDG isnt generating more interest with what they have.
- almost $10 million in vaccine sales last year
- around $1.5 million in net income (profitable)
- CEO headed China division for Chiron Vaccines
- Board of Advisors has a number of BIG names on board
- They have a Influenza vacine in market
- Doing research on H5N1 virus
- Doing research on SARS virus
- over 140 employees & researchers
- one of China's largest non-governmental vaccine producers
TEDG - bird flu research ($1.46 target price)
Ludlow Capital Issues $1.46 Price Target on TEDG on 'Bird Flu' Vaccine Acquisition
Research Staff
Last Update: May 02, 2006 - 7:36pm EST
NEW YORK--May 02, 2006--Ludlow Capital began research coverage of TechEdge (OTC:TEDG), and their new acquisition of one of China's largest non-governmental vaccine research and production companies.
CHINA BIOPHARMA ACQUISITION
On April 10, 2006, Techedge, Inc. announced that it had acquired 100% of China BioPharma Limited, a Cayman island Company. China BioPharma, Ltd. currently holds 35% ownership rights to Tianyuan Bio-pharmaceuticals (production), and 65% of China BioPharma Development Co, Ltd. (marketing, research & business development for Tianyuan Bio-pharmaceuticals). The company currently has a number of human vaccines against Influenza, Epidemic Hemorrhagic Fever, SARS, and H5N1 Avian Bird Flu.
PRICE TARGET VALUE OF $1.46
TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
http://www.theasianinvestor.com/reports/tedg.htm
TEDG target -----> $1.46 (bird flu)
PRICE TARGET VALUE OF $1.46
TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
http://www.theasianinvestor.com/reports/tedg.htm
------------
RANK BY SECTOR MARKET CAP
Ranked by market caps dated May 02, 2006. NOTE: TEDG currently has one of lowest market caps at $35 million for this sector group.
AVII = $335 million
NVAX = $311 million
GNBT = $275 million
HEB = $204 million
VICL = $203 million
SVA = $169 million
STTK = $72 million
TEDG = $35 million
RANK BY PRICE/SALES RATIO
Ranked by price to sales ratio dated May 02, 2006. P/S ratio tells investors how many times sales a stock is currently trading at.
GNBT = 1,060
HEB = 192
AVII = 70
NVAX = 43
SVA = 25
VICL = 17
TEDG = 4
STTK = NA
TEDG ---> target $1.46 (bird flu vaccine)
TEDG ----> price target = $1.46
PRICE TARGET VALUE OF $1.46
TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
http://www.theasianinvestor.com/reports/tedg.htm
------------
RANK BY SECTOR MARKET CAP
Ranked by market caps dated May 02, 2006. NOTE: TEDG currently has one of lowest market caps at $35 million for this sector group.
AVII = $335 million
NVAX = $311 million
GNBT = $275 million
HEB = $204 million
VICL = $203 million
SVA = $169 million
STTK = $72 million
TEDG = $35 million
RANK BY PRICE/SALES RATIO
Ranked by price to sales ratio dated May 02, 2006. P/S ratio tells investors how many times sales a stock is currently trading at.
GNBT = 1,060
HEB = 192
AVII = 70
NVAX = 43
SVA = 25
VICL = 17
TEDG = 4
STTK = NA
GiraSolar (GRSR) - forward split
GET IN BEFORE TUESDAY TO GET THE FORWARD SPLIT!!!
GiraSolar Announces Record Date for 5 to 2 Forward Stock Split
DEVENTER, THE NETHERLANDS, Apr 25, 2006 (MARKET WIRE via COMTEX) -- GiraSolar, Inc. (OTC: GRSR) announced today that the record date for a 5 to 2 forward split for the Company's common stock is Tuesday, May 2, 2006.
Weiland Koorstra, the President of GiraSolar, BV, commented, "Holders of the Company's common stock at the close of trading on Tuesday, May 2, 2006 will receive a 5 to 2 forward split, which we expect will then be reflected in the share price at the opening bell of Wednesday, May 03, 2006."
GRSR - 5 to 2 forward split (just out)
GiraSolar Announces Record Date for 5 to 2 Forward Stock Split
DEVENTER, THE NETHERLANDS, Apr 25, 2006 (MARKET WIRE via COMTEX) -- GiraSolar, Inc. (OTC: GRSR) announced today that the record date for a 5 to 2 forward split for the Company's common stock is Tuesday, May 2, 2006.
Weiland Koorstra, the President of GiraSolar, BV, commented, "Holders of the Company's common stock at the close of trading on Tuesday, May 2, 2006 will receive a 5 to 2 forward split, which we expect will then be reflected in the share price at the opening bell of Wednesday, May 03, 2006."
BUY 1000 SHARES NOW AND HAVE 2500 ON WED MORNING!!!
GRSR - 5 to 2 forward split (just out)
GiraSolar Announces Record Date for 5 to 2 Forward Stock Split
DEVENTER, THE NETHERLANDS, Apr 25, 2006 (MARKET WIRE via COMTEX) -- GiraSolar, Inc. (OTC: GRSR) announced today that the record date for a 5 to 2 forward split for the Company's common stock is Tuesday, May 2, 2006.
Weiland Koorstra, the President of GiraSolar, BV, commented, "Holders of the Company's common stock at the close of trading on Tuesday, May 2, 2006 will receive a 5 to 2 forward split, which we expect will then be reflected in the share price at the opening bell of Wednesday, May 03, 2006."
BUY 1000 SHARES NOW AND HAVE 2500 ON WED MORNING!!!
TEDG - .47 x .51 (real bird flu play)
RANK BY PRICE/SALES RATIO
Ranked by price to sales ratio dated April 13, 2006. P/S ratio tells investors how many times sales a stock is currently trading at.
HEB = 166
AVII = 75.5
NVAX = 40
SVA = 23.8
TEDG = 3.9
GNBT = NA
STTK = NA
http://www.wallstreetnewscast.com/sectors/biotech/birdflu/
cool...GRSR board
was gonna create one so the Germans had a place to post.
TEDG - bird flu Board of Researchers
This is powerful group of real researchers involved in bird flu research at TEDG.
* Mr. Jean-Louis Chanas - former President of Aventis Pasteur International
* Mr. John Lambert - former President of Chiron Vaccines
* Pr Dakui Yin - former Vice-Ministry of Health, former Chairman of the China Association of Preventable Medicine
* Pr Liming Li - Dean of College of Public Health of Peking University, former Director General of the China National Center for Disease Control
* Mr. Kai Zhao - Academician of the China Academy of Engineering, former Director of Beijing Institute of Biological Products
* Mr. Yongxin Yu - Academician of the China Academy of Engineering
* Pr and Ms. Xiexiu Wang - Member of the WHO (World Health Organization) Technical Advisory Group on Tuberculosis, Vice Chairman of the China Association of Preventive Medicine, Director of Tianjin Municipal Center for Disease Control and Prevention.
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - Board of Advisors (bird flu)
This is powerful group of real researchers involved in bird flu research!
* Mr. Jean-Louis Chanas - former President of Aventis Pasteur International
* Mr. John Lambert - former President of Chiron Vaccines
* Pr Dakui Yin - former Vice-Ministry of Health, former Chairman of the China Association of Preventable Medicine
* Pr Liming Li - Dean of College of Public Health of Peking University, former Director General of the China National Center for Disease Control
* Mr. Kai Zhao - Academician of the China Academy of Engineering, former Director of Beijing Institute of Biological Products
* Mr. Yongxin Yu - Academician of the China Academy of Engineering
* Pr and Ms. Xiexiu Wang - Member of the WHO (World Health Organization) Technical Advisory Group on Tuberculosis, Vice Chairman of the China Association of Preventive Medicine, Director of Tianjin Municipal Center for Disease Control and Prevention.
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - Board of Advisors (big flu people)
Looking for a real, undervalued bird flu play....check out TEDG. Here is who is with TEDG, awsome.
* Mr. Jean-Louis Chanas - former President of Aventis Pasteur International
* Mr. John Lambert - former President of Chiron Vaccines
* Prof. Dakui Yin - former Vice-Ministry of Health, former Chairman of the China Association of Preventable Medicine
* Prof. Liming Li - Dean of College of Public Health of Peking University, former Director General of the China National Center for Disease Control
* Mr. Kai Zhao - Academician of the China Academy of Engineering, former Director of Beijing Institute of Biological Products
* Mr. Yongxin Yu - Academician of the China Academy of Engineering
* Prof. and Ms. Xiexiu Wang - Member of the WHO (World Health Organization) Technical Advisory Group on Tuberculosis, Vice Chairman of the China Association of Preventive Medicine, Director of Tianjin Municipal Center for Disease Control and Prevention.
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - Board of Advisors (WOW!!)
This is powerful!
* Mr. Jean-Louis Chanas - former President of Aventis Pasteur International
* Mr. John Lambert - former President of Chiron Vaccines
* Pr Dakui Yin - former Vice-Ministry of Health, former Chairman of the China Association of Preventable Medicine
* Pr Liming Li - Dean of College of Public Health of Peking University, former Director General of the China National Center for Disease Control
* Mr. Kai Zhao - Academician of the China Academy of Engineering, former Director of Beijing Institute of Biological Products
* Mr. Yongxin Yu - Academician of the China Academy of Engineering
* Pr and Ms. Xiexiu Wang - Member of the WHO (World Health Organization) Technical Advisory Group on Tuberculosis, Vice Chairman of the China Association of Preventive Medicine, Director of Tianjin Municipal Center for Disease Control and Prevention.
http://www.theasianinvestor.com/reports/tedg.htm
STTK, GNBT, HEB, SVA, vs. TEDG
STTK vs. TEDG
RANK BY SECTOR MARKET CAP
Ranked by market caps dated April 12, 2006. NOTE: TEDG currently has one of lowest market caps at $41 million for this sector group.
GNBT = $235 million
HEB = $180 million
SVA = $158 million
STTK = $68.9 million
TEDG = $41 million
RANK BY FISCAL 2005 REVENUES
Revenues for the trailing 12 months. NOTE: TEDG did the most revenue at $10 million for this sector group. Investors are advised to check current SEC filings as some of these numbers may have changed over the running quarter.
TEDG = $10 million
SVA = $6.8 million
HEB = $1 million
STTK = $756k
GNBT = $260k
RANK BY SHARE PRICE
NOTE: TEDG is trading for the lowest price in this sector group as of closing bell on April 12, 2006.
SVA = $4.21
HEB = $2.95
GNBT = $2.65
STTK = $0.64
TEDG = $0.50
SHARE PRICE IF TEDG TRADED AT COMPETITOR MARKET CAPS
GNBT ($235 million mrkt cap) = $2.86 a share
HEB ($180 million mrkt cap) = $2.19 a share
SVA ($158 million mrkt cap) = $1.95 a share
STTK ($68.9 million mrkt cap) = $0.84 a share
TEDG (current price) = $0.50
The best comparison should be with SVA, as it's also a vaccine research company based out of China like TEDG, and did around $6.8 million in revenues for fiscal 2005. We should give SVA a premium over TEDG for being listed on the AMEX exchange, lets say 30% to be conservative. SVA currently has a market cap of around $158 million.
If SVA was valued at a 30% premium over TEDG, then TEDG should have a target market cap valuation of around $122 million. (30% of $122 million = $36.6 million + $122 million = $158 million or SVA current market cap). Note: TEDG did almost 50% more in sales revenue as compared to SVA for fiscal 2005.
Thus, TEDG should be trading at a fair price target of at least $1.48 per share compared to SVA, and others in the bird flu sector.
($122 million market cap / 82 million outstanding = $1.48 a share)
http://www.theasianinvestor.com/reports/tedg.htm
STTK vs. TEDG
STTK vs. TEDG
RANK BY SECTOR MARKET CAP
Ranked by market caps dated April 12, 2006. NOTE: TEDG currently has one of lowest market caps at $41 million for this sector group.
GNBT = $235 million
HEB = $180 million
SVA = $158 million
STTK = $68.9 million
TEDG = $41 million
RANK BY FISCAL 2005 REVENUES
Revenues for the trailing 12 months. NOTE: TEDG did the most revenue at $10 million for this sector group. Investors are advised to check current SEC filings as some of these numbers may have changed over the running quarter.
TEDG = $10 million
SVA = $6.8 million
HEB = $1 million
STTK = $756k
GNBT = $260k
RANK BY SHARE PRICE
NOTE: TEDG is trading for the lowest price in this sector group as of closing bell on April 12, 2006.
SVA = $4.21
HEB = $2.95
GNBT = $2.65
STTK = $0.64
TEDG = $0.50
SHARE PRICE IF TEDG TRADED AT COMPETITOR MARKET CAPS
GNBT ($235 million mrkt cap) = $2.86 a share
HEB ($180 million mrkt cap) = $2.19 a share
SVA ($158 million mrkt cap) = $1.95 a share
STTK ($68.9 million mrkt cap) = $0.84 a share
TEDG (current price) = $0.50
The best comparison should be with SVA, as it's also a vaccine research company based out of China like TEDG, and did around $6.8 million in revenues for fiscal 2005. We should give SVA a premium over TEDG for being listed on the AMEX exchange, lets say 30% to be conservative. SVA currently has a market cap of around $158 million.
If SVA was valued at a 30% premium over TEDG, then TEDG should have a target market cap valuation of around $122 million. (30% of $122 million = $36.6 million + $122 million = $158 million or SVA current market cap). Note: TEDG did almost 50% more in sales revenue as compared to SVA for fiscal 2005.
Thus, TEDG should be trading at a fair price target of at least $1.48 per share compared to SVA, and others in the bird flu sector.
($122 million market cap / 82 million outstanding = $1.48 a share)
http://www.theasianinvestor.com/reports/tedg.htm
STTK, HEB, GNBT, SVA, TEDG
RANK BY SECTOR MARKET CAP
Ranked by market caps dated April 12, 2006. NOTE: TEDG currently has one of lowest market caps at $41 million for this sector group.
GNBT = $235 million
HEB = $180 million
SVA = $158 million
STTK = $68.9 million
TEDG = $41 million
RANK BY FISCAL 2005 REVENUES
Revenues for the trailing 12 months. NOTE: TEDG did the most revenue at $10 million for this sector group. Investors are advised to check current SEC filings as some of these numbers may have changed over the running quarter.
TEDG = $10 million
SVA = $6.8 million
HEB = $1 million
STTK = $756k
GNBT = $260k
RANK BY SHARE PRICE
NOTE: TEDG is trading for the lowest price in this sector group as of closing bell on April 12, 2006.
HEB = $2.95
GNBT = $2.65
SVA = $1.95
STTK = $0.64
TEDG = $0.50
SHARE PRICE IF TEDG TRADED AT COMPETITOR MARKET CAPS
GNBT ($235 mrkt cap) = $2.86 a share
HEB ($180 mrkt cap) = $2.19 a share
SVA ($158 mrkt cap) = $1.95 a share
STTK ($68.9 mrkt cap) = $0.84 a share
TEDG (current price) = $0.50
The best comparison should be with SVA, as it's also a vaccine research company based out of China like TEDG, and did around $6.8 million in revenues for fiscal 2005. We should give SVA a premium above TEDG for being on the AMEX exchange, lets say 50% to be conservative. SVA is currently trading at $1.95 share price. If TEDG were trading at say $1.30 a share, then 50% above that price is SVA at $1.95. (50% of $1.30 = .65 + $1.30 = $1.95 or SVA current share price). Note: TEDG did almost 50% more in sales revenue as compared to SVA for fiscal 2005. TEDG should be trading, fairly, around $1.30 per share compared to others in the bird flu sector.
http://www.theasianinvestor.com/reports/tedg.htm
STTK, HEB, GNBT, SVA, TEDG
RANK BY SECTOR MARKET CAP
Ranked by market caps dated April 12, 2006. NOTE: TEDG currently has one of lowest market caps at $41 million for this sector group.
GNBT = $235 million
HEB = $180 million
SVA = $158 million
STTK = $68.9 million
TEDG = $41 million
RANK BY FISCAL 2005 REVENUES
Revenues for the trailing 12 months. NOTE: TEDG did the most revenue at $10 million for this sector group. Investors are advised to check current SEC filings as some of these numbers may have changed over the running quarter.
TEDG = $10 million
SVA = $6.8 million
HEB = $1 million
STTK = $756k
GNBT = $260k
RANK BY SHARE PRICE
NOTE: TEDG is trading for the lowest price in this sector group as of closing bell on April 12, 2006.
HEB = $2.95
GNBT = $2.65
SVA = $1.95
STTK = $0.64
TEDG = $0.50
SHARE PRICE IF TEDG TRADED AT COMPETITOR MARKET CAPS
GNBT ($235 mrkt cap) = $2.86 a share
HEB ($180 mrkt cap) = $2.19 a share
SVA ($158 mrkt cap) = $1.95 a share
STTK ($68.9 mrkt cap) = $0.84 a share
TEDG (current price) = $0.50
The best comparison should be with SVA, as it's also a vaccine research company based out of China like TEDG, and did around $6.8 million in revenues for fiscal 2005. We should give SVA a premium above TEDG for being on the AMEX exchange, lets say 50% to be conservative. SVA is currently trading at $1.95 share price. If TEDG were trading at say $1.30 a share, then 50% above that price is SVA at $1.95. (50% of $1.30 = .65 + $1.30 = $1.95 or SVA current share price). Note: TEDG did almost 50% more in sales revenue as compared to SVA for fiscal 2005. TEDG should be trading, fairly, around $1.30 per share compared to others in the bird flu sector.
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - bird flu vaccine
TEDG is not some company jumping on bird flu bandwagon, but one of China's largest vaccine research & production companies.
FINANCIALS
The new Chinese biotech company did $10 million in revenue, and $1.5 million in net income, profitable
MANAGEMENT
The new CEO was the head of China's division for Chiron, one of the worlds largest vaccine producers. The board of advisors contain the former CEO of Chiron (big), and a member of the WHO.
VALUATION
At 10 times sales (10 p/s ratio) would give TEDG a current market cap of $100 million. With 82 million outstanding that's fair price target of $1.20 just on fundamentals.
Current Price - .47 x .48
TEDG
TEDG - bird flu vaccine
TEDG is not some company jumping on bird flu bandwagon, but one of China's largest vaccine research & production companies.
FINANCIALS
The new Chinese biotech company did $10 million in revenue, and $1.5 million in net income, profitable
MANAGEMENT
The new CEO was the head of China's division for Chiron, one of the worlds largest vaccine producers. The board of advisors contain the former CEO of Chiron (big), and a member of the WHO.
VALUATION
At 10 times sales (10 p/s ratio) would give TEDG a current market cap of $100 million. With 82 million outstanding that's fair price target of $1.20 just on fundamentals.
Current Price - .47 x .48
TEDG - $10 million in flu vaccine sales
One of China's largest Vaccine Flu Companies
- $10 million in vaccine sales
- $1.5 million in net income, profit
- Research on SARS and Bird Flu
- CEO has big experience, Chiron
- Price target = $1.20
.49 x .54 (testing 200 day moving average)
READ THEIR NEWS!!!!
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
TEDG - read this news (.49 x .54)
One of China's largest Vaccine Flu Companies
- $10 million in vaccine sales
- $1.5 million in net income, profit
- Research on SARS and Bird Flu
- CEO has big experience, Chiron
- Price target = $1.20
.49 x .54 (testing 200 day moving average)
READ THEIR NEWS!!!!
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
OT: TEDG - 200 day MA alert (bird flu vaccine)
TEDG just acquired a large Chinese bird flu vaccine company yesterday, and TEDG looks to be breaking the 200 day moving average....this could break out this morning.
http://stockcharts.com/c-sc/sc?s=TEDG&p=D&b=5&g=0&id=t59074505080&r=1990
TEDG - .56 x .59 (bird flu acquisition)
- $10 million in sales
- $1.5 million in net income (profitable)
- Working on vaccines for SARS & Bird Flu
- New CEO was head of Chiron, worlds largest vaccine firm
- Only 82 million outstanding
- Price target $1.20 to $1.50
CHART & NEWS!!!
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f
TEDG - bird flu acquisition (BIG)
- $10 million in sales
- $1.5 million in net income (profitable)
- Working on vaccines for SARS & Bird Flu
- New CEO was head of Chiron, worlds largest vaccine firm
- Only 82 million outstanding
- Price target $1.20 to $1.50
CHART & NEWS!!!
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f...
TEDG - (read) <-------------
Bird Flu Research
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
FINANCIALS
For fiscal year 2005, Tianyuan Bio-pharmaceutical Co., Ltd. realized $9 million in sales, with a net profit of $1.5 million for the year, unaudited. The company is in the final process of completing independent audits to US GAAP standards, which should be available for public review shortly.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
TEDG - bird flu news out (READ)
H5N1 research
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
H5N1 research
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
TEDG - bird flu news out!!!!
H5N1 research
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
TEDG - real bird flu play (vaccine)
TEDG is acquiring one of China's largest flu vaccine producers.....real bird flu play.
- Have flu vaccine already in market
- Did $10 mill in sales
- Did $1.5 mill in net income
- New CEO has years of experience in vaccine research
- Stock unknown and trading below .60 a share
LOOK AT TEDG CHART
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f....
READ THE NEW CEO's BIO
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - China flu vaccine (.55)
forget STTK.....TEDG is a real vaccine producer out of China. Stock is mad cheap and just begining to hit radar screens.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f...
TEDG - CEO's bio (solid vaccine background)
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - bird flu vaccine (.58 x .61)
one of China's largest vaccine producers.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f...
OT: TEDG moving (flu vaccine)
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tedg&sid=0&o_symb=tedg&f...
TEDG - bird flu vaccine (.52 x .54)
- Acquiring one of China's biggest flu vaccine producer
- Did $10 mill in sales last year
- Did $1.5 mill in profit
- Has a flu vaccine already in the market
- Doing research on H5N1
- New CEO has 'real' background in flu vaccines
- TEDG not hyped and still cheap
- 82 mill outstanding
- Short term price target = $1.20
VALUATION RATING
Reflecting the size of TianYuan Bio-pharmaceutical research facilities and extensive background in vaccine research, and their stated revenues of $10 million for fiscal 2005, we feel it to be 'fair' to give TEDG a target market cap value of $100 million as compared to other bird flu vaccine producers trading today. TEDG currently has 82 million shares issued and outstanding, which would give TEDG a short-term valuation price target of around $1.20 a share.
http://www.theasianinvestor.com/reports/tedg.htm
TEDG DD info
- Acquiring one of China's biggest flu vaccine producer
- Did $10 mill in sales last year
- Did $1.5 mill in profit
- Has a flu vaccine already in the market
- Doing research on H5N1
- New CEO has 'real' background in flu vaccines
- TEDG not hyped and still cheap
- 82 mill outstanding
- Short term price target = $1.20
VALUATION RATING
Reflecting the size of TianYuan Bio-pharmaceutical research facilities and extensive background in vaccine research, and their stated revenues of $10 million for fiscal 2005, we feel it to be 'fair' to give TEDG a target market cap value of $100 million as compared to other bird flu vaccine producers trading today. TEDG currently has 82 million shares issued and outstanding, which would give TEDG a short-term valuation price target of around $1.20 a share.
http://www.theasianinvestor.com/reports/tedg.htm